Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT06428188 Sponsor: Essen Biotech Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT06428188
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Doctors expect you to live for at least 3 more months.
  • You have a recurring or treatment-resistant autoimmune disease (such as lupus, rheumatoid arthritis, Sjögren's syndrome, or similar conditions) that has not responded to standard treatments or has no effective treatment available.
  • A tissue sample (biopsy) has shown a specific type of damage to the bile ducts in the liver (confirm with trial site).
  • Your kidney function blood test result is within an acceptable range (confirm with trial site).
  • Your heart tracing (ECG/EKG) shows no significant problems.
  • Your blood oxygen level is above 91% without using extra oxygen.
  • Your liver function blood test results are within acceptable ranges, with some flexibility allowed for certain conditions like Gilbert syndrome (confirm with trial site).
  • You do not have any serious mental health disorders.
  • You are able to understand the trial and have signed a consent form agreeing to take part.

Who may not be able to join:

  • You have been diagnosed with a cancer (other than certain fully treated skin cancers, cervical, prostate, or breast cancers) within the last 5 years.
  • You have tested positive for Hepatitis B, Hepatitis C, HIV, or syphilis, under certain conditions related to your test results (confirm with trial site).
  • You have a serious heart condition, such as unstable chest pain, a recent heart attack, recent bypass or stent surgery (within the past 6 months), significant heart failure, or a severe irregular heartbeat.
  • You have an unstable serious illness affecting the liver, kidneys, or metabolism that requires ongoing medication.
  • You have an active or uncontrolled infection (other than a mild urinary or upper respiratory infection) that needed treatment in the 7 days before joining.
  • You are pregnant, breastfeeding, or planning to become pregnant within 2 years after the treatment — this also applies to male participants whose partners plan to become pregnant within 2 years after treatment.
  • You have previously received CAR-T cell therapy or any other gene-modified cell therapy.
  • You have taken part in another clinical trial within the past month.
  • There is evidence that your condition has spread to your brain or nervous system.
  • You have depression or thoughts of suicide.
  • The trial doctors have any other concerns that make participation unsuitable for you (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +12077706670

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Essen Biotech
Registry
ClinicalTrials.gov
Start date
29 May 2024
Est. completion
10 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of dose-limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD19/BCMA chimeric antigen receptor (CAR) T cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov